VRTX - Vertex Pharmaceuticals Inc Stock Price, Fair Value and News

495.26USD+3.00 (+0.61%)Market Closed

Market Summary

USD495.26+3.00

Market Closed

0.61%

VRTX Alerts

2 major insider sales recently.

VRTX Stock Price

View Fullscreen

VRTX RSI Chart

VRTX Valuation

Market Cap

127.8B

Price/Earnings (Trailing)

31.8

Price/Sales (Trailing)

12.55

EV/EBITDA

24.11

Price/Free Cashflow

34.38

VRTX Price/Sales (Trailing)

VRTX Profitability

EBT Margin

46.81%

Return on Equity

21.67%

Return on Assets

16.81%

Free Cashflow Yield

2.91%

VRTX Fundamentals

VRTX Revenue

Revenue (TTM)

10.2B

Rev. Growth (Yr)

13.3%

Rev. Growth (Qtr)

6.87%

VRTX Earnings

Earnings (TTM)

4.0B

Earnings Growth (Yr)

57.13%

Earnings Growth (Qtr)

13.5%

Breaking Down VRTX Revenue

Last 7 days

0.8%

Last 30 days

4.5%

Last 90 days

24.6%

Trailing 12 Months

41.7%

How does VRTX drawdown profile look like?

VRTX Financial Health

Current Ratio

3.5

VRTX Investor Care

Shares Dilution (1Y)

0.19%

Diluted EPS (TTM)

15.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	10.2B	0	0	0
2023	9.2B	9.5B	9.7B	9.9B
2022	7.9B	8.4B	8.7B	8.9B
2021	6.4B	6.7B	7.1B	7.6B
2020	4.8B	5.4B	6.0B	6.2B
2019	3.3B	3.5B	3.6B	4.2B
2018	2.4B	2.6B	2.8B	3.0B
2017	2.0B	2.1B	2.3B	2.5B
2016	1.3B	1.6B	1.7B	1.7B
2015	600.5M	628.1M	759.0M	1.0B
2014	1.0B	829.7M	787.0M	580.4M
2013	1.4B	1.3B	1.2B	1.2B
2012	1.8B	2.1B	1.8B	1.5B
2011	194.6M	277.4M	912.8M	1.4B
2010	100.3M	112.9M	111.7M	143.4M
2009	157.1M	138.7M	120.3M	101.9M
2008	0	0	0	175.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

CEO	Dr. Reshma Kewalramani FASN, M.D.
WEBSITE	vrtx.com
INDUSTRY	Biotechnology
EMPLOYEES	4800

Vertex Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Vertex Pharmaceuticals Inc? What does VRTX stand for in stocks?

VRTX is the stock ticker symbol of Vertex Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vertex Pharmaceuticals Inc (VRTX)?

As of Fri Jul 26 2024, market cap of Vertex Pharmaceuticals Inc is 127.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRTX stock?

You can check VRTX's fair value in chart for subscribers.

Is Vertex Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VRTX is over valued or under valued. Whether Vertex Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Vertex Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRTX.

What is Vertex Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, VRTX's PE ratio (Price to Earnings) is 31.8 and Price to Sales (PS) ratio is 12.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vertex Pharmaceuticals Inc's stock?

In the past 10 years, Vertex Pharmaceuticals Inc has provided 0.179 (multiply by 100 for percentage) rate of return.